PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 90 from 1 topic.Sort: Newest | Oldest
Talquetamab Infection Burden: Half Any-Grade, One-Fifth Severe
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Infectious Disease / Antimicrobials

Talquetamab raises infection concerns in RRMM patients.

Cisplatin vs Carboplatin: Only Two Comparisons Reach High-Certainty Evidence
Analysis Oncology Pharmacy Confirmatory Grade: Low

Cisplatin outperforms carboplatin in certain cancers but with higher toxicity.

Two-Sample 3-and-7-Hour Schedule Optimizes Once-Daily Busulfan TDM
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Also in Oncology

Enhance busulfan dosing with a precise two-sample strategy.

Pharmacist-Integrated Multidisciplinary Care in Pregnancy-Associated Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Also in Women's Health / Reproductive

Pharmacists enhance pregnancy-related chemotherapy care for breast cancer.

EMERALD-3: STRIDE Plus Lenvatinib and TACE Extends PFS, Not Yet OS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Moderate
Also in Gastroenterology / Hepatology

Combination therapy advances progression-free survival in liver cancer.

Fragile Efficacy Signals Underlie DOACs for Cancer-Associated VTE
Analysis Anticoagulation / Hematology Confirmatory Grade: Moderate
Also in Oncology

DOACs for cancer thrombosis: Efficacy vs. bleeding risk.

Adding Camrelizumab to TACE Plus Donafenib in PVTT-Positive HCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Gastroenterology / Hepatology

Transarterial chemoembolization with donafenib and camrelizumab may extend survival in challenging liver cancer cases.

Dual-level network meta-analysis maps first-line immunotherapy strategies in HCC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Determining the best immunotherapy strategy for advanced hepatocellular carcinoma remains a challenging decision for clinicians.

SCLC 2026: Consolidation Durvalumab, Maintenance Lurbinectedin, and Tarlatamab Reshape Care
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

New therapeutic advances redefine small cell lung cancer management.

Perioperative Enfortumab Vedotin plus Pembrolizumab Cost-Effective in Cisplatin-Ineligible MIBC
Analysis Oncology Pharmacy Confirmatory Grade: Low

Pembrolizumab plus enfortumab vedotin stands out as cost-effective for bladder cancer.

Metronomic Doxorubicin Plus Low-Dose Radiation in Preclinical Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Metronomic doxorubicin plus low-dose radiation shows promise for breast cancer.

Erdafitinib Wins Traditional Approval for FGFR3-Altered Urothelial Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Erdafitinib boosts survival in advanced FGFR3-altered bladder cancer.

NTM in Oncology: Dual Beta-Lactam Signals Warrant Study
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Very Low
Also in Oncology

NTM infections in cancer patients demand complex treatment approaches.

Causal Methods Dissolve Apparent Harm of Ibrutinib Dose Modification
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Ibrutinib dose changes in leukemia might not impact survival as once thought.

Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

CAR-T cell therapy offers new hope for recurrent glioblastoma.